Bone lesion detection with carrier-added 99mtc-edtmp in comparison with 99mtc-dpd

Nuclear Medicine Communications

Volumn 25, Issue 4, 2004, Pages 361-365

  Fueger, Barbara J ^a   Mitterhauser, Markus ^a,b   Wadsak, Wolfgang ^a,b   Ofluoglu, Sedat ^a   Traub, Tatjana ^a   Karanikas, Georgios ^a   Dudczak, Robert ^a   Pirich, Christian ^a  

^a Department of Nuclear Medicine ^*  (United States)

^b UNIVERSITY OF VIENNA   (Austria)

Author keywords

99mTc DPD; 99mTc EDTMP; Bone lesion; Bone scintigraphy; Carrier

Indexed keywords

DICARBOXYPROPANEDIPHOSPHONATE TECHNETIUM TC 99M; ETHYLENEDIAMINETETRAMETHYLENEPHOSPHONATE TECHNETIUM TC 99M; RHENIUM; TRACER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE CANCER; BONE LESION; BONE SCINTISCANNING; CANCER PATIENT; CHEMICAL STRUCTURE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HUMAN; IMAGE ANALYSIS; INJECTION; MALE; QUANTITATIVE ANALYSIS; SOFT TISSUE; STRUCTURE ANALYSIS; TIME;

AGED; AGED, 80 AND OVER; BONE AND BONES; BONE DISEASES; BONE NEOPLASMS; CLINICAL TRIALS; DIPHOSPHONATES; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MIDDLE AGED; ORGANOPHOSPHORUS COMPOUNDS; ORGANOTECHNETIUM COMPOUNDS; PROSTATIC NEOPLASMS; QUALITY CONTROL; RADIONUCLIDE IMAGING; RADIOPHARMACEUTICALS; TIME FACTORS;

EID: 2142768854     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/00006231-200404000-00008     Document Type: Article

References (11)

1. Turner JH, Martindale AA, Sorby P, Hetherington EL, Fleay RF, Hoffman RF, et al. Samarium-153 EDTMP therapy of disseminated skeletal metastasis. Eur J Nucl Med 1989; 15:784-795.
2. Farhanghi M, Holmes RA, Volkert WA, Logan KW, Singh A. Samarium-153-EDTMP: pharmacokinetics, toxicity and pain response using an escalating dose schedule in treatment of metastatic bone cancer. J Nucl Med 1992; 33:1451-1458.
3. Goeckeler WF, Edwards B, Volkert WA, Holmes RA, Simon J, Wilson D. Skeletal localization of samarium-153 chelates: potential therapeutic bone agents. J Nucl Med 1987; 28:495-504.
4. Ahonen A, Joensuu H, Hiltunen J, Hannelin M, Heikkila J, Jakobsson M, et al. Samarium-153-EDTMP in bone metastases. J Nucl Biol Med 1994; 38 (Suppl 1):123-127.
5. Noronha OP, Venkateswarlu KS. On the nature of technetium compounds. 1. A semiquantitative biological model system to assay 99mTc-complexes/radiopharmaceuticals. Eur J Nucl Med 1981; 6:121-129.
6. Mitterhauser M, Krcal A, Dudczak R, Traub T, Ofluoglu S, Viernstein H, et al. Synthesis of [99mTc]-EDTMP using perrhenic acid as carrier —radiopharmaceutical and clinical results. Eur J Nucl Med 2001; 28:OS260.
7. O'Sullivan JM, Cook GJ. A review of the efficacy of bone scanning in prostate and breast cancer. Q J Nucl Med 2002; 46:152-159.
8. Diel IJ, Solomayer EF, Bastert G. Treatment of metastatic bone disease in breast cancer: bisphosphonates. Clin Breast Cancer 2000; 1:43-51.
9. Diel IJ, Solomayer E, Costa SD, Gollan C, Goerner R, Wallwiener D, et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998; 339:357-363.
10. m-MDP bone scintigraphy. Nucl Med Commun 2001; 22:875-879.
11. Franzius C, Daldrup-Link HE, Wagner-Bohn A, Sciuk J, Heindel WL, Jurgens H, et al. FDG-PET for detection of recurrences from malignant primary bone tumors: comparison with conventional imaging. Ann Oncol 2002; 13:157-160.